Effects of a Portfolio Diet on NAFLD in Type 2 Diabetic Patients (MEDEA)
Diabetes Type 2, NAFLD

About this trial
This is an interventional treatment trial for Diabetes Type 2
Eligibility Criteria
Inclusion Criteria:
- type 2 diabetes
- non-alcoholic fatty liver disease (evaluated by US)
- HbA1c <7.5%
- LDL cholesterol <130 mg/dl
Exclusion Criteria:
- hypoglycemic therapy with sodium-glucose cotransporter (SGLT-2), pioglitazone and glucagon-like peptide (GLP-1) analogues
- severe liver and kidney failure
- recent cardiovascular events (prior 6 months)
- any other acute/chronic disease (anemia, cancer, BPCO)
Sites / Locations
- Department of Clinical Medicine and Surgery
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Portfolio Diet
MUFA Diet
The participants will follow a weight-maintaining diet characterized by whole-grain, polyphenol-rich foods, omega 3- rich foods, MUFA-rich foods (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 26%/total energy, fiber 24 g/1000Kcal) polyphenols 2715/day, omega-3 2.6 g/day and omega-6 9.6 g/day)
The participants will follow a weight-maintaining diet characterized by MUFA-rich food (olive oil) (protein 18%/total energy, carbohydrates 41%/total energy, fat 41%/total energy, MUFA 28%/total energy, fiber 10 g/1000Kcal) polyphenols 376/day, omega-3 1.1 g/day and omega-6 7.4 g/day)